Overview

Useful For
Evaluation of patients with suspected antiphospholipid syndrome by identification of beta-2 glycoprotein 1 (beta-2 GP1) IgG and IgM antibodies

Profile Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Reporting Name</th>
<th>Available Separately</th>
<th>Always Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>GB2GP</td>
<td>Beta 2 GP1 Ab IgG, S</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>MB2GP</td>
<td>Beta 2 GP1 Ab IgM, S</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Method Name
Enzyme-Linked Immunosorbent Assay (ELISA)

NY State Available
Yes

Specimen

Specimen Type
Serum

Specimen Required

Container/Tube:
Preferred: Serum gel
Acceptable: Red top

Specimen Volume: 0.5 mL

Forms
If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.

Specimen Minimum Volume
0.4 mL

Reject Due To

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross hemolysis</td>
<td>Reject</td>
</tr>
<tr>
<td>Gross lipemia</td>
<td>Reject</td>
</tr>
<tr>
<td>Gross icterus</td>
<td>OK</td>
</tr>
</tbody>
</table>

Specimen Stability Information

Document generated April 9, 2020 at 2:47pm CDT
Clinical and Interpretive

Clinical Information

Beta-2 glycoprotein 1 (beta-2 GP1, also called apolipoprotein H) is a 326-amino acid polypeptide synthesized by hepatocytes, endothelial cells, and trophoblast cells. It contains 5 homologous domains of approximately 60 amino acids each.(1,2) Domain 5, located at the C terminus, contains a hydrophobic core surrounded by 14 positively charged amino acid residues that promote electrostatic interactions with plasma membranes via interactions with negatively charged phospholipids. Complexes of beta-2 GP1 and phospholipids in vivo reveal epitopes that react with natural autoantibodies.(3) Plasma from normal individuals contains low concentrations of IgG autoantibodies to beta-2 GP1 (beta-2 GP1 antibodies) that are of moderate affinity and react with an epitope on the first domain near the N terminus.

Pathologic levels of beta-2 GP1 antibodies occur in patients with antiphospholipid syndrome (APS). APS is associated with a variety of clinical symptoms, notably, thrombosis, pregnancy complications, unexplained cutaneous circulatory disturbances (livido reticularis or pyoderma gangrenosum), thrombocytopenia or hemolytic anemia, and nonbacterial thrombotic endocarditis. Beta-2 GP1 antibodies are found with increased frequency in patients with systemic rheumatic diseases, especially systemic lupus erythematosus.

Beta-2 GP1 antibodies are detected in the clinical laboratory by different types of assays including immunoassays and functional coagulation assays. Immunoassays for beta-2 GP1 antibodies can be performed using either a composite substrate comprised of beta-2 GP1 plus anionic phospholipid (eg, cardiolipin or phosphatidylserine), or beta-2 GP1 alone. Antibodies detected by immunoassays that utilize composite substrates are commonly referred to as phospholipid or cardiolipin antibodies. Antibodies detected using beta-2 GP1 substrate without phospholipid (so called direct assays) are referred to simply as beta-2 GP1 antibodies. Some beta-2 GP1 antibodies are capable of inhibiting clot formation in functional coagulation assays that contain low concentrations of phospholipid cofactors. Antibodies detected by functional coagulation assays are commonly referred to as lupus anticoagulants.

The diagnosis of APS requires at least 1 clinical criteria and 1 laboratory criteria be met.(4) The clinical criteria include vascular thrombosis (arterial or venous in any organ or tissue) and pregnancy morbidity (unexplained fetal death, premature birth, severe preeclampsia, or placental insufficiency). Other clinical manifestations, including heart valve disease, livedo reticularis, thrombocytopenia, nephropathy, neurological symptoms, are often associated with APS but are not included in the diagnostic criteria. The laboratory criteria for diagnosis of APS are the presence of lupus anticoagulant, the presence of IgG and/or IgM antcardiolipin antibody (>40 GPL, >40 MPL, or >99th percentile), and/or the presence of IgG and/or IgM beta-2 GP1 antibody (>99th percentile). All antibodies must be demonstrated on 2 or more occasions separated by at least 12 weeks. Direct assays for beta-2 GP1 antibodies have been reported to be somewhat more specific (but less sensitive) for disease diagnosis in patients with APS.(5) Anticardiolipin and beta-2 GP1 antibodies of the IgA isotype are not part of the laboratory criteria for APS due to lack of specificity.

Reference Values

<15.0 U/mL (negative)
15.0-39.9 U/mL (weakly positive)
Test Definition: B2GMG
Beta 2 GP1 Ab, IgM/IgG, S

40.0-79.9 U/mL (positive)
> or =80.0 U/mL (strongly positive)

Results are expressed in arbitrary units and apply to IgG and IgM values.

Reference values apply to all ages.

Interpretation
Strongly positive results for beta-2 glycoprotein 1 (beta-2 GP1) antibodies (>40 U/mL for IgG and/or IgM) are diagnostic criterion for antiphospholipid syndrome (APS). Lesser levels of beta-2 GP1 antibodies and antibodies of the IgA isotype may occur in patients with clinical signs of APS, but the results are not considered diagnostic. Beta-2 GP1 antibodies must be detected on 2 or more occasions at least 12 weeks apart to fulfill the laboratory diagnostic criteria for APS.

Detection of beta-2 GP1 antibodies is not affected by anticoagulant treatment.

Cautions
The immunoassay for beta-2 glycoprotein 1 (beta-2 GP1) antibodies does not distinguish between autoantibodies and antibodies produced in response to infectious agents or as epiphenomena following thrombosis. For this reason, a single positive test result is not sufficient to meet accepted serologic criteria for the diagnosis of antiphospholipid syndrome (see Clinical Information).

Comparative studies and interlaboratory proficiency surveys indicate that results of beta-2 GP1 antibody tests can be highly variable and results obtained with different commercial immunoassays may yield substantially different results.(4)

Clinical Reference

Performance
Method Description
Purified beta-2 GPI antigen is bound to the wells of a polystyrene microwell plate under conditions that will preserve the antigen in its native state. Prediluted controls and diluted patient sera are added to separate wells, allowing any beta-2 GP1 IgM or IgG antibodies present to bind to the immobilized antigen. Unbound sample is washed away and an enzyme-labeled antihuman IgM conjugate is added to each well. A second incubation allows the enzyme-labeled antihuman IgM or IgG to bind to any patient antibodies that have become attached to the microwells. After washing
away any unbound enzyme-labeled antihuman IgM or IgG, the remaining enzyme activity is measured by adding a chromogenic substrate and measuring the intensity of the color that develops. The assay can be evaluated spectrophotometrically by measuring and comparing the color intensity that develops in the patient wells with that of a 5-point calibration curve. Results are reported out semiquantitatively in standard IgM anti-beta-2 GPI units (SMU) and standard IgG anti-beta-2 GPI units (SGU). (Package Inserts: QUANTA Lite beta 2 GP1 IgM ELISA, Inova Diagnostics, February 2015 Revision 13 and QUANTA Lite 2[2] GP1 IgG ELISA, Inova Diagnostics, March 2016 Revision 18)

PDF Report
No

Day(s) and Time(s) Test Performed
Monday through Saturday; 8 a.m.

Analytic Time
Same day/1 day

Maximum Laboratory Time
6 days

Specimen Retention Time
14 days

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information
86146 x 2

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>B2GMG</td>
<td>Beta 2 GP1 Ab, IgM/IgG, S</td>
<td>In Process</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GB2GP</td>
<td>Beta 2 GP1 Ab IgG, S</td>
<td>44448-9</td>
</tr>
<tr>
<td>Result ID</td>
<td>Test Result Name</td>
<td>Result LOINC Value</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>MB2GP</td>
<td>Beta 2 GP1 Ab IgM, S</td>
<td>44449-7</td>
</tr>
</tbody>
</table>